Artios
Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team of DDR drug developers.
Cambridge, UKwww.artiospharma.com ↗
Total raised
€259M
€258,579,748
Funding rounds
3
Investors
24
distinct backers
Active since
2016-08
latest 2025-11
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood49
base rate 53% for Series D+
- ▲ In typical raise window
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood24
base rate 12% (2+ rounds)
- ▲ 3 rounds raised
- ▲ €100M+ raised
- ▲ 10y since founding
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-11-17 | Series D+ | €99M | Andera Partners,Avidity Partners,EQT Life Sciences,Invus,IP Group PLC,Janus Henderson Investors+9 more | View deal → |
| 2021-07-27 | Series C | €129M | Avidity Partners,CaaS Capital Management,Deep Track Capital,Invus,Omega Funds,Piper Heartland Healthcare Capital+6 more | View deal → |
| 2016-09-01 | Series A | €30M | Abbvie Biotech Ventures,Imperial Innovations Limited,SV Life Sciences | View deal → |
Investors
24Abbvie Biotech VenturesAndera PartnersAvidity PartnersCaaS Capital ManagementDeep Track CapitalEQT Life SciencesImperial Innovations LimitedInvusIP Group PLCJanus Henderson InvestorsM VenturesNovartis Venture FundOmega FundsPfizer VenturesPiper Heartland Healthcare CapitalRA Capital ManagementRTW Investments LPSchroders CapitalSofinnova PartnersSoleus CapitalSV Health InvestorsSV Life SciencesTCG XTetragon Financial Group Limited